David Myles Sells 51,000 Shares of Olema Pharmaceuticals (NASDAQ:OLMA) Stock

Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) insider David Myles sold 51,000 shares of Olema Pharmaceuticals stock in a transaction that occurred on Friday, December 19th. The stock was sold at an average price of $30.46, for a total transaction of $1,553,460.00. Following the completion of the sale, the insider owned 551,881 shares of the company’s stock, valued at $16,810,295.26. This represents a 8.46% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Olema Pharmaceuticals Stock Down 1.2%

Shares of Olema Pharmaceuticals stock opened at $27.34 on Thursday. Olema Pharmaceuticals, Inc. has a twelve month low of $2.86 and a twelve month high of $36.26. The company has a quick ratio of 8.03, a current ratio of 8.03 and a debt-to-equity ratio of 0.01. The company’s 50 day moving average is $18.92 and its 200 day moving average is $10.68. The company has a market cap of $1.88 billion, a price-to-earnings ratio of -14.62 and a beta of 1.87.

Olema Pharmaceuticals (NASDAQ:OLMA) last announced its earnings results on Monday, November 10th. The company reported ($0.49) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.44) by ($0.05). Research analysts anticipate that Olema Pharmaceuticals, Inc. will post -2.33 EPS for the current year.

Trending Headlines about Olema Pharmaceuticals

Here are the key news stories impacting Olema Pharmaceuticals this week:

• Positive Sentiment: Seeking Alpha reiterates a “Strong Buy” on Olema driven by initiation of the OPERA‑02 pivotal trial and promising combo data (palazestrant + KISQALI), highlighting OPERA‑01 readout in 2H‑2026 and OPERA‑02 topline in 2028 as key value catalysts. Seeking Alpha – Strong Buy on OPERA‑02
• Positive Sentiment: Several sell‑side firms have raised targets and reiterated buys (Goldman, Citi, JPMorgan, UBS), lifting the consensus price target (~$40.50 average), which supports upside if clinical milestones land.
• Neutral Sentiment: Reported short interest data shows effectively zero shares short and a 0.0 days‑to‑cover figure, indicating short sellers are not currently positioned to amplify moves (data appears to show no measurable short interest for December).
• Negative Sentiment: Director Ian T. Clark sold 264,800 shares on Dec. 19 at ~$29.73 (≈$7.87M), a large director‑level disposal that can raise governance/lockup concern and pressure the stock. SEC Form 4 – Clark sale 12/19/2025
• Negative Sentiment: Naseem Zojwalla executed multiple large sales (100,000; 70,000; 99,509 shares across Dec. 19–23), reducing his stake materially and generating roughly $7.5M+ in proceeds across those trades. SEC Form 4 – Zojwalla sales
• Negative Sentiment: David C. Myles sold 51,000 shares on Dec. 19 at ~$30.46 (~$1.55M), trimming his holding by ~8.5%—another insider sale contributing to near‑term selling pressure. SEC Form 4 – Myles sale 12/19/2025

Institutional Investors Weigh In On Olema Pharmaceuticals

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Susquehanna International Group LLP raised its stake in Olema Pharmaceuticals by 20.6% during the 3rd quarter. Susquehanna International Group LLP now owns 112,277 shares of the company’s stock worth $1,099,000 after acquiring an additional 19,182 shares during the period. Quarry LP purchased a new stake in shares of Olema Pharmaceuticals in the third quarter worth $184,000. Paradigm Biocapital Advisors LP raised its position in shares of Olema Pharmaceuticals by 0.4% during the 3rd quarter. Paradigm Biocapital Advisors LP now owns 6,794,172 shares of the company’s stock valued at $66,515,000 after purchasing an additional 30,000 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new stake in shares of Olema Pharmaceuticals during the 3rd quarter valued at $268,000. Finally, Kingdon Capital Management L.L.C. purchased a new position in shares of Olema Pharmaceuticals during the 3rd quarter valued at $8,361,000. 91.78% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of equities research analysts have issued reports on the company. HC Wainwright boosted their price target on Olema Pharmaceuticals from $36.00 to $45.00 and gave the company a “buy” rating in a research note on Thursday, December 11th. Citigroup boosted their target price on shares of Olema Pharmaceuticals from $21.00 to $60.00 and gave the company a “buy” rating in a research report on Friday, December 12th. Oppenheimer upped their target price on shares of Olema Pharmaceuticals from $45.00 to $48.00 and gave the company an “outperform” rating in a report on Thursday, December 11th. Guggenheim began coverage on shares of Olema Pharmaceuticals in a research note on Wednesday, October 8th. They set a “buy” rating and a $20.00 price target on the stock. Finally, The Goldman Sachs Group boosted their price objective on shares of Olema Pharmaceuticals from $26.00 to $38.00 and gave the company a “buy” rating in a research report on Thursday, December 11th. Seven equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Olema Pharmaceuticals has a consensus rating of “Moderate Buy” and an average target price of $40.50.

About Olema Pharmaceuticals

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.